Skip to main content
Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ELDN ISIN · US67011N2045 LEI · 549300S17CAM13O43606 US Professional, scientific and technical activities
Filings indexed 585 across all filing types
Latest filing 2015-12-17 Director's Dealing
Country US United States of America
Listing US ELDN

About Eledon Pharmaceuticals, Inc.

https://eledon.com/

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing immune-modulating therapies for organ transplantation and autoimmune diseases. The company's mission, "One Transplant for Life," focuses on improving transplant longevity and the quality of life for recipients. Its lead product candidate, tegoprubart, is an anti-CD40 Ligand (CD40L) antibody designed to regulate the immune system to prevent organ rejection. Eledon has completed a Phase 2 clinical trial evaluating tegoprubart in kidney transplant recipients and is advancing the compound into late-stage development. The company is also exploring tegoprubart's potential in other applications, including liver transplantation and xenotransplantation.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2015-12-17 English
PRIMARY DOCUMENT
Director's Dealing
2015-12-17 English
PRIMARY DOCUMENT
Director's Dealing
2015-11-12 English
FORM 10-Q
Interim / Quarterly Report Q3 2015
2015-11-10 English
Regulatory Filings 2015
Regulatory Filings
2015-10-26 English
Capital/Financing Update 2015
Capital/Financing Update Classification · 95% confidence The document is a letter from Tokai Pharmaceuticals, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-3. It references Rule 461 under the Securities Act of 1933 and discusses procedural acknowledgments related to the registration statement's effectiveness. The document is short (1966 characters) and is a formal request related to a capital markets filing, specifically a registration statement for securities issuance. This type of document is an update on financing activities and capital structure changes, not a full report or financial statement. Therefore, it fits best under the category Capital/Financing Update (CAP).
2015-10-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.